These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26842909)

  • 1. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data.
    Chen ZW; Li H; Ren H; Hu P
    Sci Rep; 2016 Feb; 6():20310. PubMed ID: 26842909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.
    Patiño-Galindo JÁ; Salvatierra K; González-Candelas F; López-Labrador FX
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2402-16. PubMed ID: 26856832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
    Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
    PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
    Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
    Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
    Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
    Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
    Vercauteren K; Brown RJ; Mesalam AA; Doerrbecker J; Bhuju S; Geffers R; Van Den Eede N; McClure CP; Troise F; Verhoye L; Baumert T; Farhoudi A; Cortese R; Ball JK; Leroux-Roels G; Pietschmann T; Nicosia A; Meuleman P
    Gut; 2016 Dec; 65(12):2029-2034. PubMed ID: 26306759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.
    Dietz J; Susser S; Berkowski C; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2015; 10(8):e0134395. PubMed ID: 26317755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
    Zhang Y; Cao Y; Zhang R; Zhang X; Lu H; Wu C; Huo N; Xu X
    PLoS One; 2016; 11(11):e0165658. PubMed ID: 27812165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.
    Li Z; Liu Y; Zhang Y; Shao X; Luo Q; Guo X; Lin G; Cai Q; Zhao Z; Chong Y
    Biomed Res Int; 2017; 2017():9849823. PubMed ID: 29164151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    Dietz J; Müllhaupt B; Buggisch P; Graf C; Peiffer KH; Matschenz K; Schattenberg JM; Antoni C; Mauss S; Niederau C; Discher T; Trauth J; Dultz G; Schulze Zur Wiesch J; Piecha F; Klinker H; Müller T; Berg T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C; ; ; ;
    J Hepatol; 2023 Jan; 78(1):57-66. PubMed ID: 36031158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing.
    Bergfors A; Leenheer D; Bergqvist A; Ameur A; Lennerstrand J
    Antiviral Res; 2016 Feb; 126():81-9. PubMed ID: 26707078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
    Peres-da-Silva A; Brandão-Mello CE; Lampe E
    Antivir Ther; 2017; 22(5):447-451. PubMed ID: 28085003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.
    Tavares RCF; Feldner ACCA; Pinho JRR; Uehara SNO; Emori CT; Carvalho-Filho RJ; Silva ISS; Santana RAF; de Castro VFD; Castoli GTF; Cristovão CU; Ferraz MLCG
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):754-758. PubMed ID: 28234637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
    Sede MM; Laufer NL; Quarleri J
    Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.
    Karbalaie Niya MH; Salman-Tabar S; Bokharaei-Salim F; Behmanesh M; Keyvani H
    Microb Pathog; 2017 Apr; 105():166-170. PubMed ID: 28161357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
    Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
    Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.